Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jasmanda Wu

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Clinical Therapeutics|December 5, 2016
The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future DirectionJasmanda Wu, Juhaeri Juhaeri
BMC Pulmonary Medicine|December 3, 2022
Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settingsTimothy Aksamit, Jasmanda Wu, Mariam Hassan, et al.
Cancer Epidemiology|March 5, 2015
Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasmJasmanda Wu, Ling Zhang, Anjali Vaze, et al.
Pharmacoepidemiology and Drug Safety|February 1, 2020
Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directionsJasmanda Wu, Cunlin Wang, Sengwee Toh, et al.
Annals of General Psychiatry|February 13, 2009
Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based studyFrank D Gianfrancesco, Gahan Pandina, Ramy Mahmoud, et al.
Diabetes, Obesity & Metabolism|November 25, 2020
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?Dídac Mauricio, Jukka Westerbacka, Charlie Nicholls, et al.
Diabetes, Obesity & Metabolism|July 13, 2019
Early hypoglycaemia and adherence after basal insulin initiation in a nationally representative sample of Medicare beneficiaries with type 2 diabetesPengxiang Li, Zhi Geng, Vrushabh P Ladage, et al.
ERJ Open Research|July 5, 2023
Pulmonary exacerbations in insured patients with bronchiectasis over 2 yearsPatrick A Flume, Joseph Feliciano, Matthew Lucci, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 15, 2007
Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infectionsAlan D Tice, Robin S Turpin, Christopher T Hoey, et al.
Psychopharmacology Bulletin|September 10, 2008
Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trialsGahan J Pandina, Dennis A Revicki, Leah Kleinman, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Clinical Therapeutics|December 5, 2016
The US Food and Drug Administration's Risk Evaluation and Mitigation Strategy (REMS) Program - Current Status and Future DirectionJasmanda Wu, Juhaeri Juhaeri
BMC Pulmonary Medicine|December 3, 2022
Impact of initiation of amikacin liposome inhalation suspension on hospitalizations and other healthcare resource utilization measures: a retrospective cohort study in real-world settingsTimothy Aksamit, Jasmanda Wu, Mariam Hassan, et al.
Cancer Epidemiology|March 5, 2015
Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasmJasmanda Wu, Ling Zhang, Anjali Vaze, et al.
Pharmacoepidemiology and Drug Safety|February 1, 2020
Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directionsJasmanda Wu, Cunlin Wang, Sengwee Toh, et al.
Annals of General Psychiatry|February 13, 2009
Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based studyFrank D Gianfrancesco, Gahan Pandina, Ramy Mahmoud, et al.
Diabetes, Obesity & Metabolism|November 25, 2020
How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real-world setting?Dídac Mauricio, Jukka Westerbacka, Charlie Nicholls, et al.
Diabetes, Obesity & Metabolism|July 13, 2019
Early hypoglycaemia and adherence after basal insulin initiation in a nationally representative sample of Medicare beneficiaries with type 2 diabetesPengxiang Li, Zhi Geng, Vrushabh P Ladage, et al.
ERJ Open Research|July 5, 2023
Pulmonary exacerbations in insured patients with bronchiectasis over 2 yearsPatrick A Flume, Joseph Feliciano, Matthew Lucci, et al.
American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists|May 15, 2007
Comparative costs of ertapenem and piperacillin-tazobactam in the treatment of diabetic foot infectionsAlan D Tice, Robin S Turpin, Christopher T Hoey, et al.
Psychopharmacology Bulletin|September 10, 2008
Psychometric evaluation of a patient-rated troubling symptom scale for generalized anxiety disorder clinical trialsGahan J Pandina, Dennis A Revicki, Leah Kleinman, et al.
Pageof 2